IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v41y2018i9d10.1007_s40264-018-0668-9.html
   My bibliography  Save this article

Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis

Author

Listed:
  • Géric Maura

    (French National Health Insurance (Caisse Nationale de l’Assurance Maladie/CNAM)
    University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology-UMR 1219)

  • Cécile Billionnet

    (French National Health Insurance (Caisse Nationale de l’Assurance Maladie/CNAM))

  • Joël Coste

    (French National Health Insurance (Caisse Nationale de l’Assurance Maladie/CNAM))

  • Alain Weill

    (French National Health Insurance (Caisse Nationale de l’Assurance Maladie/CNAM))

  • Anke Neumann

    (French National Health Insurance (Caisse Nationale de l’Assurance Maladie/CNAM))

  • Antoine Pariente

    (University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology-UMR 1219
    CHU de Bordeaux, Pharmacologie)

Abstract

Introduction Postmarketing pharmacovigilance reports have raised concerns about non-bleeding adverse events associated with direct oral anticoagulants (DOACs), but only limited results are available from large claims databases. Objective The aim of this study was to assess the potential association between DOAC initiation and the onset of four types of non-bleeding adverse events by sequence symmetry analysis (SSA). Methods SSA was performed using nationwide data from the French National Healthcare databases (Régime Général, 50 million beneficiaries) to assess a cohort of 386,081 DOAC new users for the first occurrence of four types of non-bleeding outcomes: renal, hepatic, skin outcomes identified by using hospitalization discharge diagnoses, and gastrointestinal outcomes by using medication reimbursement. Asymmetry in the distribution of each investigated outcome occurring before and after initiation of DOAC therapy was used to test the association between DOAC therapy and these outcomes. SSA inherently controls for time-constant confounders, and adjusted sequence ratios were computed after correcting for temporal trends. Negative (glaucoma) and positive (bleeding, depressive disorders) control outcomes were used and analyses were replicated on a cohort of 310,195 patients initiating a vitamin K antagonist (VKA). Results This study demonstrated the expected positive association between either DOAC or VKA therapy and hospitalised bleeding and initiation of antidepressant therapy, while no association was observed between either DOAC or VKA therapy and initiation of antiglaucoma medications. For DOAC therapy, signals were the associations with hepatic outcomes, including acute liver injury [for the 3-month time window, aSR3 = 2.71, 95% confidence interval (CI) 1.79–4.52]; gastrointestinal outcomes, including initiation of drugs for constipation and antiemetic drugs (aSR3 = 1.31, 95% CI 1.27–1.36; and 1.17, 95% CI 1.12–1.22, respectively); and kidney diseases (aSR3 = 1.33, 95% CI 1.29–1.37). Conclusion Results of this nationwide study suggest that DOACs are associated with rare but severe liver injury and more frequent gastrointestinal disorders. A low risk of kidney injury with DOAC therapy can also not be excluded.

Suggested Citation

  • Géric Maura & Cécile Billionnet & Joël Coste & Alain Weill & Anke Neumann & Antoine Pariente, 2018. "Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis," Drug Safety, Springer, vol. 41(9), pages 881-897, September.
  • Handle: RePEc:spr:drugsa:v:41:y:2018:i:9:d:10.1007_s40264-018-0668-9
    DOI: 10.1007/s40264-018-0668-9
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-018-0668-9
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-018-0668-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Emanuel Raschi & Matteo Bianchin & Walter Ageno & Roberto De Ponti & Fabrizio De Ponti, 2016. "Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies," Drug Safety, Springer, vol. 39(12), pages 1175-1187, December.
    2. Maja Hellfritzsch & Lotte Rasmussen & Jesper Hallas & Anton Pottegård, 2018. "Using the Symmetry Analysis Design to Screen for Adverse Effects of Non-vitamin K Antagonist Oral Anticoagulants," Drug Safety, Springer, vol. 41(7), pages 685-695, July.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Emanuel Raschi & Matteo Bianchin & Milo Gatti & Alessandro Squizzato & Fabrizio De Ponti, 2019. "Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews," Drug Safety, Springer, vol. 42(12), pages 1409-1422, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Emanuel Raschi & Matteo Bianchin & Milo Gatti & Alessandro Squizzato & Fabrizio De Ponti, 2019. "Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews," Drug Safety, Springer, vol. 42(12), pages 1409-1422, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:41:y:2018:i:9:d:10.1007_s40264-018-0668-9. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.